ACTRN12608000181303招募中3 期
Detection of recombinant human luteinising hormone as a doping agent in healthy male volunteers aged 18 to 45. An open label, randomised clinical study.
Sydney South Western Area Health Service (SSWAHS)0 个研究点目标入组 64 人开始时间: 2008年4月10日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 45 Years（—）
- 性别
- Male
入选标准
- •Healthy males
排除标准
- •No recent history of steriod use
研究者
相似试验
尚未招募
3 期
Development of valid immunoassay methods for Luteinising Hormone (LH) in urine.ACTRN12609000300279Sydney South Western Area Health Service (SSWAHS)4
已完成
Unknown
Measurement of luteinizing hormone surge in vaginal dischargehealthy adultJPRN-UMIN000052859Miura Clinic, Medical Corporation Kanonkai40
尚未招募
不适用
Detection of Indirect Androgen Doping with a GnRH Analog (Leuprolide)ACTRN12609000629235Sydney South West Area Health Authority (SSWAHS)16
已完成
不适用
Does the addition of Recombinant Luteinising Hormone (recLH) (Luveris) to a regimen of Recombinant Follicle Stimulating Hormone (recFSH) (Gonal-F) and Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide) improve ovarian response and implantation rates in patients age >35 years undergoing in vitro fertilisation (IVF)/embryo transfer (ET)?SubfertilityUrological and Genital DiseasesFemale infertilityISRCTN10841210VU University Medical Centre (VUMC) (Netherlands)600
招募中
不适用
The effect of luteinizing hormone-releasing hormone antagonist in the progression prostate cancer with initial luteinizing hormone-releasing hormone agonistprostate cancerJPRN-UMIN000009079M-CURE32